- Trials with a EudraCT protocol (17)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
17 result(s) found for: polatuzumab.
Displaying page 1 of 1.
| EudraCT Number: 2017-002023-21 | Sponsor Protocol Number: GO39942 | Start Date*: 2018-08-31 | |||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
| Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB AND CHP (R-CHP) VERSUS RITUXIMAB ... | |||||||||||||
| Medical condition: Diffuse large B-cell lymphoma (DLBCL) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Trial now transitioned) CZ (Trial now transitioned) PT (Completed) BE (Trial now transitioned) AT (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-001039-29 | Sponsor Protocol Number: GO40515 | Start Date*: 2019-02-26 | |||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
| Full Title: A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED, CONTROLLED STUDY INVESTIGATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF MOSUNETUZUMAB (BTCT4465A) IN COMBINATION WITH CHOP OR ... | |||||||||||||
| Medical condition: B-Cell Non-Hodgkin Lymphoma (B-cell NHL) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) AT (Completed) ES (Ongoing) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-001361-28 | Sponsor Protocol Number: GO29365 | Start Date*: 2015-10-07 | |||||||||||||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd. | |||||||||||||||||||||||
| Full Title: A Phase Ib/II study evaluating the safety, tolerability and anti-tumor activity of polatuzumab vedotin in combination with rituximab (R) or obinutuzumab (G) plus bendamustine (B) in relapsed or ref... | |||||||||||||||||||||||
| Medical condition: Follicular Lymphoma and Diffuse Large B-Cell Lymphoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: CZ (Completed) HU (Completed) DE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) NL (Completed) FR (Ongoing) IT (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2021-000468-32 | Sponsor Protocol Number: CLSG-MCL-POLA | Start Date*: 2021-09-17 | |||||||||||
| Sponsor Name:Kooperativní lymfomová skupina, z.s. | |||||||||||||
| Full Title: A phase II, open-label, study of polatuzumab-vedotin in combination with bendamustine and rituximab for patients with mantle cell lymphoma, who relapse after previous therapy with Bruton tyrosine k... | |||||||||||||
| Medical condition: Mantle cell lymphoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-004845-25 | Sponsor Protocol Number: BO29561 | Start Date*: 2016-08-23 | |||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd. | |||||||||||||
| Full Title: A phase Ib/II study evaluating the safety and efficacy of obinutuzumab in combination with atezolizumab plus polatuzumab vedotin in patients with relapsed or refractory follicular lymphoma and ritu... | |||||||||||||
| Medical condition: Follicular Lymphoma (FL) or Diffuse Large B-cell Lymphoma (DLBCL) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) PL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-006030-40 | Sponsor Protocol Number: Pola_R | Start Date*: 2022-05-31 |
| Sponsor Name:Med. Univ. Wien, Klinik f. Innere Med I, Onkologie | ||
| Full Title: EFFICACY OF POLATUZUMAB, BENDAMUSTINE AND RITUXIMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MANTLE CELL LYMPHOMA – A SINGLE CENTER PHASE II TRIAL | ||
| Medical condition: MANTLE CELL LYMPHOMA | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: AT (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2019-000842-36 | Sponsor Protocol Number: Version128May2019 | Start Date*: 2020-04-07 | |||||||||||
| Sponsor Name:The Clatterbridge Cancer Centre NHS Foundation Trust | |||||||||||||
| Full Title: A Polatuzumab Vedotin Containing Chemo-Immunotherapeutic Regimen in Patients with Diffuse Large B-Cell Lymphoma Unsuitable for Full Dose R-CHOP Therapy | |||||||||||||
| Medical condition: Diffuse large B-cell lymphoma in patients with co-morbidities who cannot tolerate full dose R-CHOP. | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-003727-10 | Sponsor Protocol Number: MO40598 | Start Date*: 2019-12-16 | |||||||||||||||||||||
| Sponsor Name: Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F.Hoffmann-La Roche Ltd | |||||||||||||||||||||||
| Full Title: A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY EVALUATING THE SAFETY AND EFFICACY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB PLUS GEMCITABINE PLUS OXALIPLATIN (R-GEMOX) VERSUS R-G... | |||||||||||||||||||||||
| Medical condition: Relapsed/refractory diffuse large B-cell lymphoma (DLBL) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: ES (Ongoing) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) IE (Completed) FI (Completed) SE (Completed) IT (Trial now transitioned) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2018-003889-14 | Sponsor Protocol Number: NLG-LBC7 | Start Date*: 2020-04-07 | |||||||||||
| Sponsor Name:Skåne University Hospital, Department of Oncology | |||||||||||||
| Full Title: R-MINI-CHOP versus R-MINI-CHP in combination with polatuzumab-vedotin, as primary treatment for patients with diffuse large B-cell lymphoma, ≥80 years, or frail ≥75 years – an open label randomized... | |||||||||||||
| Medical condition: Diffuse large B-cell lymphoma. | |||||||||||||
|
|||||||||||||
| Population Age: Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Trial now transitioned) NO (Trial now transitioned) DK (Trial now transitioned) FI (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-001998-40 | Sponsor Protocol Number: GO29833 | Start Date*: 2016-03-01 | |||||||||||||||||||||
| Sponsor Name:F. HOFFMANN - LA ROCHE LTD. | |||||||||||||||||||||||
| Full Title: A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA AND RITUXIM... | |||||||||||||||||||||||
| Medical condition: Relapsed or refractory, follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2022-003398-51 | Sponsor Protocol Number: R-Pola-Glo | Start Date*: 2023-03-05 | |||||||||||
| Sponsor Name:Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest | |||||||||||||
| Full Title: A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate polatuzumab vedotin and the bispecific antibody glofitamab in... | |||||||||||||
| Medical condition: aggressive large B-cell lymphoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: AT (Ongoing) DE (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-001999-22 | Sponsor Protocol Number: GO29834 | Start Date*: 2016-02-25 | |||||||||||||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd. | |||||||||||||||||||||||
| Full Title: A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR DIFFUSE LARGE B... | |||||||||||||||||||||||
| Medical condition: Relapsed or refractory, follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: ES (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2018-001141-13 | Sponsor Protocol Number: GO40516 | Start Date*: 2020-02-21 | |||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||||||||||||||||||||||||||||||||
| Full Title: AN OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE Ib/II TRIAL EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF MOSUNETUZUMAB (BTCT4465A) IN COMBINATION WITH POLATUZUMAB VEDOTIN IN... | |||||||||||||||||||||||||||||||||||||||||||
| Medical condition: B-cell non-Hodgkin lymphoma (NHL) | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Prematurely Ended) ES (Ongoing) BE (Trial now transitioned) | |||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2011-004377-84 | Sponsor Protocol Number: GO27834 | Start Date*: 2013-04-11 | ||||||||||||||||||||||||||
| Sponsor Name:Genentech, Inc. | ||||||||||||||||||||||||||||
| Full Title: A randomized, open-label, multicenter, phase II trial evaluating the safety and activity of pinatuzumab vedotin (DCDT2980S) in combination with rituximab or polatuzumab vedotin (DCDS4501A) in combi... | ||||||||||||||||||||||||||||
| Medical condition: Follicular Non-Hodgkin’s Lymphoma (FL); Diffuse Large B-Cell Lymphoma (DLBCL) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: DE (Completed) IT (Completed) NL (Completed) FR (Completed) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2019-002962-10 | Sponsor Protocol Number: MO40599/GLA2017-R2 | Start Date*: 2021-05-03 | ||||||||||||||||||||||||||
| Sponsor Name:GWT-TUD GmbH | ||||||||||||||||||||||||||||
| Full Title: An open-label, prospective Phase III clinical study to compare polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) with rituximab, ifosfamide, carboplatin and eto... | ||||||||||||||||||||||||||||
| Medical condition: primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: AT (Trial now transitioned) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2020-003908-14 | Sponsor Protocol Number: M-2020-371 | Start Date*: 2021-07-07 | ||||||||||||||||
| Sponsor Name:Miltenyi Biomedicine GmbH | ||||||||||||||||||
| Full Title: A pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with relapsed/refractory diff... | ||||||||||||||||||
| Medical condition: Relapsed/refractory diffuse large B cell lymphoma (R-R DLBCL) | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: SE (Trial now transitioned) LT (Trial now transitioned) AT (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) HU (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2021-005725-24 | Sponsor Protocol Number: M22-132 | Start Date*: 2022-04-25 | |||||||||||||||||||||
| Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||||||||||||
| Full Title: Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin Lymphoma | |||||||||||||||||||||||
| Medical condition: B-cell Non-Hodgkin's lymphoma, diffuse large B-cell lymphoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: ES (Ongoing) FR (Trial now transitioned) NL (Trial now transitioned) DK (Trial now transitioned) HU (Trial now transitioned) DE (Trial now transitioned) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
